17. p-ANCA: perinuclear staining pattern (MPO)
c-ANCA: cytoplasmic staining pattern (PR3)
Atypical: other staining pattern (Other)
Recommended to check both indirect immunofluorescence and ELISA, at least initially
19. DISEASE ASSOCIATIONS
ANCA GPA MPA EGPA
cANCA (PR3) 80% 40% 10%
pANCA (MPO) 15% 50% 60%
Negative 5% 10% 30%
ANCA specificity predicts pattern of organ involvement
False Positives common in infections such as tuberculosis, malaria and leprosy
24. POLYARTERITIS NODOSA
Treat HBV or HCV if present
Prognosis worse if old
Prognosis worse if cardiac, GI, renal
disease
Often one episode but 5y relapse is 25%
Necrotising vasculitis of
medium-sized arterioles
Renal microaneurysms
25. IGA VASCULITIS (HSP)
Child or teenager
Palpable purpura
Arthralgia
Abdominal pain (intussusception)
Hypertension
Haematuria (nephrotic syndrome)
Early relapse
Granular IgA and C3 in walls
of small blood vessels
Fibrinoid necrosis
Palpable purpura
26. BEHÇET DISEASE
More severe in young males
Recurrent mucocutaneous ulceration
Inflammatory eye disease
Asymmetric non-erosive polyarthritis
Arterial and venous disease
Pathergy
No diagnostic test
27. TAKAYASU ARTERITIS
~ 20% of vasculitis in India
Young women
Lower abdominal aorta
Renovascular hypertension
‘Pulseless disease’
Imaging for diagnosis
Imaging for monitoring (?)
Vascular intervention and AVR
Indian Takayasu Clinical Activity Score
Mandal et al (2015) Ind J Rheumatol
Angiography
CT Angiography
Doppler Ultrasound
30. TREATMENT
• Prednisolone
• Urgent high doses (~1 mg/kg) if temporal arteritis
• Monitor with symptoms and ESR/CRP
• Significant side effects in ~80%
• Wean over months
• ‘Steroid-sparing’ drugs
• Some evidence for Methotrexate but not strong
• Only ~ 20% remain in remission with steroids
alone
• Biologics
• TNF blockers not effective
• Anti-IL-6 (Tocilizumab) recently approved
• Bone protection
• Bisphosphonates, calcium and vitamin D
Steroids
Steroid-sparing drugs
Biologics
Bone protection
31. ANCA-ASSOCIATED VASCULITIS
80% one year mortality without treatment
Induce remission with minimal toxicity
Maintain remission and minimise damage
32. REMISSION INDUCTION
• Cyclophosphamide
• IV Pulses 15 mg/kg over ~ 3 months
• Reduced dose compared to oral induction
• Counselling
• Prednisolone
• IV Pulses of Methylprednisolone 1 g/d x3
• Oral Prednisolone 1 mg/kg tapering over ~ 3
months
• Plasma exchange
• Severe renal failure
• Anti-CD20 MAb (Rituximab/Mabthera)
• Infusion 375 mg /week x4
• Alternative to Cyclophosphamide (eg if PR3
ANCA)
Regime depends on severity
33. REMISSION MAINTENANCE
• Azathioprine
• 2 mg/kg/d
• Check TPMT levels if available (?)
• Prednisolone
• 10-15 mg/d
• Significant adverse effects
• Anti-CD20 MAb (Rituximab/Mabthera)
• Remission induction after relapse & maintenance
• Preferable to more Cyclophosphamide / Azathioprine
• Risk of hypogammaglobulinemia
• Methotrexate
• More likely to relapse
• Greater requirement for steroids
• Can be continued if used for induction
• Avoid with Bactrim (sometimes used for nasal
disease)
Relapse in 70% over 10 years
More common if PR3 ANCA
Eliminate Staph aureus from nose
35. CO-MORBIDITIES
• Infection
• PJP prophylaxis while on Cyclophosphamide
• Latent TB reactivation
• Immunization
• Cardiovascular
• Vascular risk factors
• Hypertension
• Renal impairment
• RRT and transplantation
• Metabolic
• Osteoporosis
• Diabetes
• Cancer
• Urothelial cancer if exposed to Cyclophosphamide
• Lymphoma and skin cancer
Now major cause of morbidity & mortality
36. EGPA
• Improved remission induction
• Increased time to first relapse
• Reduced steroid use
Anti-interleukin 5 mAb
biozentrum.uni-wuerzburg.de
EGPA
• Improved remission induction
• Increased time to first relapse
• Reduced steroid use
Anti-interleukin 5 mAb
biozentrum.uni-wuerzburg.de